Related Experiment Video

Updated: Jun 3, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

[Adverse effects of new biological therapies for non-small-cell bronchial cancer]

Marion Castel1, Atul Pathak, Fabien Despas

  • 1Université de Toulouse III (Paul Sabatier), faculté de médecine, CHU de Toulouse, institut des maladies métaboliques et cardiovasculaires, fédération des services de cardiologie, service de pharmacologie clinique, Inserm U1048, 31000 Toulouse, France.

Presse Medicale (Paris, France : 1983)
|March 12, 2011
PubMed

Insights

Biological therapies for bronchial cancer present unique toxicities. Management requires multidisciplinary care to address side effects like skin issues, bleeding, and hypertension.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Biological therapies for bronchial cancer differ in mechanism from chemotherapy, leading to distinct toxicities.
  • Understanding these specific toxicities is crucial for patient management.

Purpose of the Study:

  • To outline the toxicities associated with biological therapies for bronchial cancer.
  • To provide guidance on managing these adverse events.

Main Methods:

  • Review of known side effect profiles for EGFR inhibitors and antiangiogenic agents.
  • Discussion of recommended management strategies for identified toxicities.

Main Results:

  • EGFR inhibitors commonly cause cutaneous toxicity, manageable with supportive care.
  • Antiangiogenic agents are associated with increased bleeding risk (nosebleeds, hemoptysis) and arterial thrombosis.
  • Hypertension is a frequent side effect, controllable with standard antihypertensive treatments.

Conclusions:

  • Effective management of biological therapy toxicities requires a collaborative approach involving oncologists, organ specialists, and general practitioners.
  • Multidisciplinary care ensures optimal handling of frequent but generally non-severe drug-related events.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...